Article
Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Aug 2009
Nicoletto Maria Ornella, Bertorelle Roberta, Borgato Lucia, De Salvo Gian Luca, Artioli Grazia, Lombardi Giuseppe, Zustovich Fable, Marcato Raffaella, Parenti Anna, Montagna Marco, Donach Martin E
Abstract excerpt
BACKGROUND: The aim of the study was to assess the efficacy of pegylated liposomal doxorubicin (PLD) and oxaliplatin in patients affected by relapsed epithelial ovarian cancer with a family history of BRCA and p53 mutations. METHODS: Seventy-two women received a median of 7.5 courses of PLD at 30 to 35 mg/m2 plus oxaliplatin at 70 mg/m2, and associations between BRCA1/2 and TP53 status and overall survival (OS)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.